Abstract: A display assembly, a display device and a driving method for the display assembly are provided. The display assembly includes: a dimming array (10) and a pixel array (20) stacked together; wherein the dimming array (10) includes a plurality of dimming units (101) arranged in an array; the pixel array (20) includes a plurality of pixel units (201) arranged in an array; each dimming unit (101) corresponds to at least one pixel unit (201), and different dimming units (101) correspond to different pixel units (201), respectively. The display assembly further includes: a first driver chip (102) configured to drive the dimming array (10). The number of output channels of the first driver chip (102) is equal to the number of columns of dimming units (101) in the dimming array (10), and each output channel of the first driver chip (102) is connected to one column of dimming units (101).

Abstract: Provided is a display system, including one or more display screens (11, 12), a plurality of source drivers (13, 14), a timing controller (15) and a graphics processing unit (16). Each display screen (11, 12) is connected to one or more source drivers (13, 14). The graphic processing unit (16) is connected to the timing controller (15). The timing controller (15) is connected to the plurality of source drivers (13, 14). The graphic processing unit (16) is configured to determine each image of the one or more display screens (11, 12) and transmit the image to the timing controller (15). The timing controller (15) is configured to divide each image of the one or more display screens (11, 12) into a plurality of sub-images in a P2P transmission manner, and output in parallel the corresponding sub-images to the plurality of source drivers (13, 14).

Abstract: The present disclosure provides a display substrate and a display device, belonging to the field of display technology, which can solve the problem that a splicing gap between existing adjacent display substrates of a spliced screen is relatively wide, and a narrow-bezel display cannot be realized. The display substrate of the present disclosure has a display area and a non-display area surrounding the display area; the display substrate includes a base and a plurality of pixel units located on the base and arranged in the display area; each of the pixel units includes a pixel circuit. The display substrate further includes: a light detection circuit located on the base and arranged in the non-display area; where the light detection circuit is configured to detect brightness of ambient light.

Abstract: A display assembly, a display device and a driving method for the display assembly are provided. The display assembly includes: a dimming array (10) and a pixel array (20) stacked together; wherein the dimming array (10) includes a plurality of dimming units (101) arranged in an array; the pixel array (20) includes a plurality of pixel units (201) arranged in an array; each dimming unit (101) corresponds to at least one pixel unit (201), and different dimming units (101) correspond to different pixel units (201), respectively. The display assembly further includes: a first driver chip (102) configured to drive the dimming array (10). The number of output channels of the first driver chip (102) is equal to the number of columns of dimming units (101) in the dimming array (10), and each output channel of the first driver chip (102) is connected to one column of dimming units (101).

Abstract: Provided is a display system, including one or more display screens (11, 12), a plurality of source drivers (13, 14), a timing controller (15) and a graphics processing unit (16). Each display screen (11, 12) is connected to one or more source drivers (13, 14). The graphic processing unit (16) is connected to the timing controller (15). The timing controller (15) is connected to the plurality of source drivers (13, 14). The graphic processing unit (16) is configured to determine each image of the one or more display screens (11, 12) and transmit the image to the timing controller (15). The timing controller (15) is configured to divide each image of the one or more display screens (11, 12) into a plurality of sub-images in a P2P transmission manner, and output in parallel the corresponding sub-images to the plurality of source drivers (13, 14).

Abstract: The present disclosure provides a display substrate and a display device, belonging to the field of display technology, which can solve the problem that a splicing gap between existing adjacent display substrates of a spliced screen is relatively wide, and a narrow-bezel display cannot be realized. The display substrate of the present disclosure has a display area and a non-display area surrounding the display area; the display substrate includes a base and a plurality of pixel units located on the base and arranged in the display area; each of the pixel units includes a pixel circuit. The display substrate further includes: a light detection circuit located on the base and arranged in the non-display area; where the light detection circuit is configured to detect brightness of ambient light.

Abstract: The present invention relates to the field of biopharmaceuticals, and in particular to a protein, a protein conjugate, a pharmaceutical composition and its use for treating diabetes. The fusion protein of the present invention is obtained by linking two polypeptides, wherein one polypeptide is an interleukin-1 receptor antagonistic protein or an analogue thereof, and another polypeptide is GLP-1 receptor binding polypeptide or an analogue thereof, or an insulin receptor binding polypeptide or an analogue thereof, or a GIP receptor binding polypeptide or an analogue thereof. The fusion proteins of the present invention and conjugates thereof have a significant efficacy in treating diabetes, and can be used in a lower dose, resulting in marked reduction in side effects.

Abstract: This application discloses a display device. The display device includes a display module, a frame surrounding the sides of the display module, a backlight module stacked with the display module, and a backplane. The frame includes holes. The backplane includes a main plane, side walls, and protrusions. The main plane is located on a side of the backlight module away from the display module. The side walls extend from the edges of the main plane toward the display module and are perpendicular to the main plane. The protrusions are located on the side walls and each of the protrusions is embedded in a corresponding one of the holes of the frame.

Abstract: This application discloses a display device. The display device includes a display module, a frame surrounding the sides of the display module, a backlight module stacked with the display module, and a backplane. The frame includes holes. The backplane includes a main plane, side walls, and protrusions. The main plane is located on a side of the backlight module away from the display module. The side walls extend from the edges of the main plane toward the display module and are perpendicular to the main plane. The protrusions are located on the side walls and each of the protrusions is embedded in a corresponding one of the holes of the frame.

Abstract: A soluble dietary fiber having a xylooligosaccharide purity of 70% or greater. The xylooligosaccharide has a total xylobiose and xylotriose content of 45% or great. The soluble dietary fiber has a higher content of an effective component, thus improving the proliferation of a Bifidobacterium and Lactobacillus, and significantly reducing blood glucose.

Abstract: The present invention relates to the field of biopharmaceuticals, and in particular to a protein, a protein conjugate, a pharmaceutical composition and its use for treating diabetes. The fusion protein of the present invention is obtained by linking two polypeptides, wherein one polypeptide is an interleukin-1 receptor antagonistic protein or an analogue thereof, and another polypeptide is GLP-1 receptor binding polypeptide or an analogue thereof, or an insulin receptor binding polypeptide or an analogue thereof, or a GIP receptor binding polypeptide or an analogue thereof. The fusion proteins of the present invention and conjugates thereof have a significant efficacy in treating diabetes, and can be used in a lower dose, resulting in marked reduction in side effects.

Abstract: The present invention relates to the field of biopharmaceuticals, and in particular to a protein, a protein conjugate, a pharmaceutical composition and its use for treating diabetes. The fusion protein of the present invention is obtained by linking two polypeptides, wherein one polypeptide is an interleukin-1 receptor antagonistic protein or an analogue thereof, and another polypeptide is GLP-1 receptor binding polypeptide or an analogue thereof, or an insulin receptor binding polypeptide or an analogue thereof, or a GIP receptor binding polypeptide or an analogue thereof. The fusion proteins of the present invention and conjugates thereof have a significant efficacy in treating diabetes, and can be used in a lower dose, resulting in marked reduction in side effects.

Abstract: A soluble dietary fiber having a xylooligosaccharide purity of 70% or greater. The xylooligosaccharide has a total xylobiose and xylotriose content of 45% or great. The soluble dietary fiber has a higher content of an effective component, thus improving the proliferation of a bifidobacterium and lactobacillus, and significantly reducing blood glucose.

Abstract: The present invention relates to the field of biopharmaceutics, and in particular to a protein, a protein conjugate, a pharmaceutical composition and its use for treating diabetes. The fusion protein of the present invention is obtained by linking two polypeptides, wherein one polypeptide is an interleukin-1 receptor antagonistic protein or an analog thereof, and another polypeptide is GLP-1 receptor binding polypeptide or an analog thereof, or an insulin receptor binding polypeptide or an analog thereof, or a GIP receptor binding polypeptide or an analog thereof. The fusion proteins of the present invention and conjugates thereof have a significant efficacy in treating diabetes, and can be used in a lower dose, resulting in a marked reduction in side effects.

Abstract: The present invention relates to the field of biopharmaceuticals, and in particular to a protein, a protein conjugate, a pharmaceutical composition and its use for treating diabetes. The fusion protein of the present invention is obtained by linking two polypeptides, wherein one polypeptide is an interleukin-1 receptor antagonistic protein or an analogue thereof, and another polypeptide is GLP-1 receptor binding polypeptide or an analogue thereof, or an insulin receptor binding polypeptide or an analogue thereof, or a GIP receptor binding polypeptide or an analogue thereof. The fusion proteins of the present invention and conjugates thereof have a significant efficacy in treating diabetes, and can be used in a lower dose, resulting in marked reduction in side effects.

Abstract: The present invention relates to the field of biopharmaceutics, and in particular to a protein, a protein conjugate, a pharmaceutical composition and its use for treating diabetes. The fusion protein of the present invention is obtained by linking two polypeptides, wherein one polypeptide is an interleukin-1 receptor antagonistic protein or an analogue thereof, and another polypeptide is GLP-1 receptor binding polypeptide or an analogue thereof, or an insulin receptor binding polypeptide or an analogue thereof, or a GIP receptor binding polypeptide or an analogue thereof. The fusion proteins of the present invention and conjugates thereof have a significant efficacy in treating diabetes, and can be used in a lower dose, resulting in a marked reduction in side effects.